This article was originally published Feb. 6.
Following the burst of next-generation sequencing technologies onto the scene, Sanger sequencing may have slipped out of the limelight, but it is still laboring away in a few laboratories.
Robert Lyons, the director of the University of Michigan DNA Sequencing Core, said that while he has seen a decline in demand for Sanger sequencing, it has not been large. "The business has gone down about 10 percent," he said. "We still do 300,000 samples or 300,000 reactions a year here."